We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.20 | 0.19% | 1,697.80 | 1,696.40 | 1,696.80 | 1,701.00 | 1,686.40 | 1,695.20 | 7,755,918 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.17 | 69.84B |
Date | Subject | Author | Discuss |
---|---|---|---|
06/9/2018 08:05 | Yes, except that, for new products/application | tradermichael | |
06/9/2018 08:02 | clients do most of their orders on line now days of sales reps are becoming redundant | doohoma3 | |
06/9/2018 01:00 | TM,No Retired just use IG. | garycook | |
05/9/2018 08:40 | I'm with AJ Bell, do you work for IG, Gary? | tradermichael | |
04/9/2018 11:10 | GlaxoSmithKline PLC (GSK.L) Already an IG client? Log in to trade SELL 1577.80 BUY 1578.20 0.6 -6.60pts (-0.42%) High: 1593.4 Low: 1578.0 91% of client accounts are long on this market | garycook | |
02/9/2018 16:15 | UK pharmaceuticals group GlaxoSmithKline (GSK) will begin production at a new factory in the UAE in 2020, according to the company’s general manager for the Gulf region. In an interview with Gulf News, GSK regional general manager Sally Storey said that the company is “looking at options” for its UAE facility. “It may be that we don’t build something, we may look [to go] through a partnership,” the newspaper quoted her as saying. “We are relatively advanced in that right now. We’re looking at about six products initially.” | tradermichael | |
01/9/2018 10:58 | Cannot explain it either. At the bottom line of the upward trend channel right now ….. sorry, bad description (my performance last week also says I'm no chartist!) | tradermichael | |
31/8/2018 19:28 | So an important AZN advanced biologics trial,TULIP 1 Phase III for Lupus, fails and the sector gets kicked, fine - but can someone explain to me why GSK got kicked even harder than AZN? AZN down 1.7% GSK down 2%. FFS. | romeike | |
31/8/2018 14:43 | Ready for a bounce off the upward trend line? | tradermichael | |
30/8/2018 11:53 | Liberum Capital lowered from buy to hold today but increased its target price from 1630p to 1700p ( just put on for you guys I don't hold any at the moment) | jpjohn1 | |
30/8/2018 10:26 | Super news... "GSK's treatment for children with severe asthma receives EU approval" Have to feel for Astra Zeneca though... Positive news on T2 diabetes device offset by: "The U.S. Food and Drug Administration said on Wednesday a serious genital infection has been reported in patients taking SGLT2 inhibitors, a certain class of diabetes drugs approved for AstraZeneca Plc and several other firms." Yikes! | fangorn2 | |
30/8/2018 09:24 | Yes I am collecting filters! | abdullla | |
30/8/2018 08:29 | Abdul here as well when is he going to e u a site | doohoma3 | |
30/8/2018 07:50 | RTTNews) - GlaxoSmithKline (GSK, GSK.L) announced that the European Commission has granted marketing authorisation for Nucala (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients aged six up to 17 years. As a result of the licence extension Nucala is now approved for use for severe refractory eosinophilic asthma in both adult and paediatric patients in the 31 European countries covered by the European Medicines Agency. Nucala is the first and only approved biologic therapy for paediatric patients with severe asthma that targets interleukin-5, which plays an important role in regulating the function of eosinophils. | tradermichael | |
30/8/2018 07:43 | Good timing | abdullla | |
30/8/2018 07:13 | IN ... 3489 shares @ 1584.178p | tradermichael | |
29/8/2018 10:36 | rikky - posted something on my thread - IMO it could move sharply either way in sterling terms. (Remain long at present). | alphorn | |
29/8/2018 10:35 | Could see this treading water around the £16 mark for the next few months. Any other views, whether bullish or bearish? | rikky72 | |
28/8/2018 07:04 | thecashmoney 27 Aug '18 - 18:11 - 18028 of 18028 (Filtered) | tradermichael | |
27/8/2018 17:11 | Check nuog ,well worth a look if you're looking for growth from low cap ,deal expected shortly . | thecashmoney | |
27/8/2018 17:10 | Just do your own research and ignore the noise is my advice,it's quite obvious that NUOG /MFDEVCO is on the cusp of transformational news .Comms from the company via tweets says negotiations are drawing to a conclusion,last rns from chairman states it's progressing .Recent podcast designed to be non promotional imvho .Think of it like buying a car ,you don't tell the other parties how much you love it ,you say it needs new tyres , exhaust is on its way out etc ,you want the best deal possible . According to my research it's a win win win for all involved. OSX-3 owners want more from their asset , dommo current operators need cash revenue to raise to develop other assets.Mfdevco obviously will be truly transformational as the podcast states it will put mfdevco in a very forward position,with most of the steps allready completed,alot of money has already been spent and will put this company in a very advanced state compared to its current market capitalisation.CM | thecashmoney | |
25/8/2018 01:57 | The new Barron's agrees with you TraderMichael. They think Shingrix could generate $2 billion annual sales by 2022.Quote:Shares of Glaxo have returned 21%, 13 percentage points more than the S&P 500 index, since we recommended them late last year.They still look cheap at 14 times this year's projected earnings. Investors have begun to recognize the company's new growth drivers, but still don't give it credit for its pipeline of products in development, according to UBS analyst Michael Leuchten. For shareholders, there's no hurry to sell. | richard xii | |
24/8/2018 14:28 | Yes, they are putting a 1790p price on it. Additionally, I think the potential for Shingrix has not been fully appreciated as well …. ;0) | tradermichael | |
24/8/2018 13:00 | Berenberg Says Glaxo HIV Drug Cabotegravir Is UnderratedBerenberg reiterated its Buy rating on GlaxoSmithKline saying the drugmaker's Cabotegravir treatment has been under-appreciated by the market... | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |